Alkermes Plc (ALKS)vsUnited Therapeutics Corporation (UTHR)
ALKS
Alkermes Plc
$42.80
-1.34%
HEALTHCARE · Cap: $7.38B
UTHR
United Therapeutics Corporation
$549.87
+0.40%
HEALTHCARE · Cap: $23.17B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 103% more annual revenue ($3.17B vs $1.56B). UTHR leads profitability with a 40.6% profit margin vs 9.8%. ALKS appears more attractively valued with a PEG of 1.96. UTHR earns a higher WallStSmart Score of 57/100 (C).
ALKS
Hold44
out of 100
Grade: D
UTHR
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+52.3%
Fair Value
$73.21
Current Price
$42.80
$30.41 discount
Margin of Safety
+2.5%
Fair Value
$487.82
Current Price
$549.87
$62.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 28.2% year-over-year
Keeps 41 of every $100 in revenue as profit
Strong operational efficiency at 41.7%
Safe zone — low bankruptcy risk
Every $100 of equity generates 22 in profit
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Earnings declined 67.0%
Negative free cash flow — burning cash
Expensive relative to growth rate
Revenue declined 1.6%
Earnings declined 12.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : ALKS
The strongest argument for ALKS centers on Revenue Growth. Revenue growth of 28.2% demonstrates continued momentum.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 40.6% and operating margin at 41.7%.
Bear Case : ALKS
The primary concerns for ALKS are PEG Ratio, P/E Ratio, EPS Growth. A P/E of 49.2x leaves little room for execution misses.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
ALKS profiles as a growth stock while UTHR is a declining play — different risk/reward profiles.
UTHR carries more volatility with a beta of 0.57 — expect wider price swings.
ALKS is growing revenue faster at 28.2% — sustainability is the question.
UTHR generates stronger free cash flow (363M), providing more financial flexibility.
Bottom Line
UTHR scores higher overall (57/100 vs 44/100), backed by strong 40.6% margins. ALKS offers better value entry with a 52.3% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alkermes Plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Alkermes plc, a biopharmaceutical company, researches, develops and markets pharmaceutical products to address the unmet medical needs of patients in various therapeutic areas in the United States, Ireland and internationally. The company is headquartered in Dublin, Ireland.
Visit Website →United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?